1069 related articles for article (PubMed ID: 28346348)
1. Vitamin D in Chronic Kidney Disease and Dialysis Patients.
Jean G; Souberbielle JC; Chazot C
Nutrients; 2017 Mar; 9(4):. PubMed ID: 28346348
[TBL] [Abstract][Full Text] [Related]
2. Current treatment options for secondary hyperparathyroidism in patients with stage 3 to 4 chronic kidney disease and vitamin D deficiency.
Galassi A; Ciceri P; Porata G; Iatrino R; Boni Brivio G; Fasulo E; Magagnoli L; Stucchi A; Frittoli M; Cara A; Cozzolino M
Expert Opin Drug Saf; 2021 Nov; 20(11):1333-1349. PubMed ID: 33993809
[No Abstract] [Full Text] [Related]
3. Low-dose cholecalciferol supplementation and dual vitamin D therapy in haemodialysis patients.
Dusilová-Sulková S; Šafránek R; Vávrová J; Horáček J; Pavlíková L; Palička V
Int Urol Nephrol; 2015 Jan; 47(1):169-76. PubMed ID: 25262147
[TBL] [Abstract][Full Text] [Related]
4. Cholecalciferol v. ergocalciferol for 25-hydroxyvitamin D (25(OH)D) repletion in chronic kidney disease: a randomised clinical trial.
Wetmore JB; Kimber C; Mahnken JD; Stubbs JR
Br J Nutr; 2016 Dec; 116(12):2074-2081. PubMed ID: 28065190
[TBL] [Abstract][Full Text] [Related]
5. High-dose cholecalciferol reduces parathyroid hormone in patients with early chronic kidney disease: a pilot, randomized, double-blind, placebo-controlled trial.
Alvarez JA; Law J; Coakley KE; Zughaier SM; Hao L; Shahid Salles K; Wasse H; Gutiérrez OM; Ziegler TR; Tangpricha V
Am J Clin Nutr; 2012 Sep; 96(3):672-9. PubMed ID: 22854402
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of High vs. Conventional Ergocalciferol Dose for Increasing 25-Hydroxyvitamin D and Suppressing Parathyroid Hormone Levels in Stage III-IV CKD with Vitamin D Deficiency/Insufficiency: A Randomized Controlled Trial.
Thimachai P; Supasyndh O; Chaiprasert A; Satirapoj B
J Med Assoc Thai; 2015 Jul; 98(7):643-8. PubMed ID: 26267985
[TBL] [Abstract][Full Text] [Related]
7. Serum 24,25-dihydroxyvitamin D
Graeff-Armas LA; Kaufmann M; Lyden E; Jones G
Clin Nutr; 2018 Jun; 37(3):1041-1045. PubMed ID: 28506446
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
9. Management of secondary hyperparathyroidism in stages 3 and 4 chronic kidney disease.
Andress DL; Coyne DW; Kalantar-Zadeh K; Molitch ME; Zangeneh F; Sprague SM
Endocr Pract; 2008; 14(1):18-27. PubMed ID: 18238737
[TBL] [Abstract][Full Text] [Related]
10. Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.
Massart A; Debelle FD; Racapé J; Gervy C; Husson C; Dhaene M; Wissing KM; Nortier JL
Am J Kidney Dis; 2014 Nov; 64(5):696-705. PubMed ID: 24856872
[TBL] [Abstract][Full Text] [Related]
11. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
12. Calcifediol to treat secondary hyperparathyroidism in patients with chronic kidney disease.
Galassi A; Bellasi A; Ciceri P; Pivari F; Conte F; Cozzolino M
Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1073-1084. PubMed ID: 28846459
[TBL] [Abstract][Full Text] [Related]
13. [Cholecalciferol supplementation improves secondary hyperparathyroidism control in hemodialysis patients].
Massimetti C; Bellasi A; Feriozzi S
G Ital Nefrol; 2020 Jun; 37(3):. PubMed ID: 32530156
[No Abstract] [Full Text] [Related]
14. Do the benefits of using calcitriol and other vitamin D receptor activators in patients with chronic kidney disease outweigh the harms?
Toussaint ND; Damasiewicz MJ
Nephrology (Carlton); 2017 Mar; 22 Suppl 2():51-56. PubMed ID: 28429545
[TBL] [Abstract][Full Text] [Related]
15. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
16. Survey of attitudes of physicians toward the current evaluation and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Souqiyyeh MZ; Shaheen FA
Saudi J Kidney Dis Transpl; 2010 Jan; 21(1):93-101. PubMed ID: 20061700
[TBL] [Abstract][Full Text] [Related]
17. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low.
Ennis JL; Worcester EM; Coe FL; Sprague SM
J Nephrol; 2016 Feb; 29(1):63-70. PubMed ID: 25736620
[TBL] [Abstract][Full Text] [Related]
18. Native vitamin D in pre-dialysis chronic kidney disease.
Cardoso MP; Pereira LAL
Nefrologia (Engl Ed); 2019; 39(1):18-28. PubMed ID: 30274806
[TBL] [Abstract][Full Text] [Related]
19. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
20. Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.
Kovesdy CP; Lu JL; Malakauskas SM; Andress DL; Kalantar-Zadeh K; Ahmadzadeh S
Am J Kidney Dis; 2012 Jan; 59(1):58-66. PubMed ID: 21885174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
